parp1 inhibitor imp1734
Generic: PARP1 Inhibitor IMP1734
parp1 inhibitor imp1734: 1 clinical trial tracked.
parp1 inhibitor imp1734 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about parp1 inhibitor imp1734, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
Primary endpoint: Number of subjects with adverse events, treatment emergent adverse events or serious adverse events
Interventionalopen156 targetStarted 2023-12Completion 2027-1250 sites · Australia, Canada, China, Denmark…Eikon Therapeutics